In: Commentaries

Don’t throw the baby out with the bathwater
December 22, 2023

 The pressure to replace animal research with non-animal methods is growing. Earlier this year, NIH has issued a “Request for Information…

Read More
“Home inspections” for life sciences companies going public before clinical proof of concept
December 22, 2023

For over a decade, there is a trend of less specialized investment firms and public equity investors betting on life sciences…

Read More
“Publication of negative/null results discussed at NIH”
November 2, 2022

NINDS Office of Research Quality has presented a proposal on how to address the publication bias. It can be watched HERE (starts at…

Read More
“The customer is king!” 
November 2, 2022

Once during our vacation in Greece, our children asked for ice cream after having dinner.  When the waiter was asked about…

Read More
“Hold your horses!”
November 2, 2022

Risk of Alzheimer’s disease nearly doubles in older adults with Covid-19!  Like many of you, several weeks ago we have also…

Read More
“The Steal syndrome – or the FDA Modernization Act to end animal testing requirement passes U.S. Senate”
November 2, 2022

On September 29, 2022, the U.S. Senate passed the FDA Modernization Act 2.0, S.5002, by unanimous consent. While it is unclear…

Read More
Archimedes‘ fulcrum and the “reproducibility” debate
June 16, 2022

We like to cite Dorothy Bishop who wrote several years ago: “We know how to formulate and test hypotheses in controlled…

Read More
“Serial de-risking”: Quod licet Iovi non licet bovi?
June 16, 2022

When it comes to novel therapies, positive data has justifiably more value than negative or null data.  Indeed, positive data promises…

Read More
Pre-study odds
March 14, 2022

One of the key themes in the 2005 seminal paper by John Ioannidis “Why most published research findings are false” is…

Read More
Preparing for a journey
February 27, 2022

Recently, I went on a trip to a nice hotel with a swimming pool. Upon arrival, standing in the modern room…

Read More